Free Trial

OVERSEA CHINESE BANKING Corp Ltd Takes $30.17 Million Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Regeneron Pharmaceuticals logo with Medical background

Key Points

  • OVERSEA CHINESE BANKING Corp Ltd has invested approximately $30.17 million in Regeneron Pharmaceuticals, acquiring 47,567 shares in the process.
  • Analysts have mixed ratings on Regeneron, with one sell rating, seven holds, sixteen buys, and two strong buys, reflecting a consensus rating of "Moderate Buy."
  • Regeneron recently reported earnings of $8.22 per share, missing estimates, and had a revenue of $3.03 billion, down 3.7% year-over-year.
  • Want stock alerts on Regeneron Pharmaceuticals? Get 5 Weeks of MarketBeat All Access for $5. Get My Stock Alerts.

OVERSEA CHINESE BANKING Corp Ltd bought a new position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 47,567 shares of the biopharmaceutical company's stock, valued at approximately $30,168,000.

A number of other institutional investors also recently modified their holdings of the stock. TIAA Trust National Association raised its stake in shares of Regeneron Pharmaceuticals by 1,187.4% during the first quarter. TIAA Trust National Association now owns 26,018 shares of the biopharmaceutical company's stock worth $16,501,000 after buying an additional 23,997 shares during the last quarter. UNIVEST FINANCIAL Corp raised its stake in shares of Regeneron Pharmaceuticals by 29.7% during the first quarter. UNIVEST FINANCIAL Corp now owns 18,419 shares of the biopharmaceutical company's stock worth $11,682,000 after buying an additional 4,217 shares during the last quarter. Moors & Cabot Inc. raised its stake in shares of Regeneron Pharmaceuticals by 7.6% during the first quarter. Moors & Cabot Inc. now owns 845 shares of the biopharmaceutical company's stock worth $536,000 after buying an additional 60 shares during the last quarter. Howland Capital Management LLC raised its stake in shares of Regeneron Pharmaceuticals by 72.9% during the first quarter. Howland Capital Management LLC now owns 26,688 shares of the biopharmaceutical company's stock worth $16,926,000 after buying an additional 11,251 shares during the last quarter. Finally, US Bancorp DE raised its stake in shares of Regeneron Pharmaceuticals by 4.6% during the first quarter. US Bancorp DE now owns 6,345 shares of the biopharmaceutical company's stock worth $4,024,000 after buying an additional 279 shares during the last quarter. 83.31% of the stock is owned by institutional investors.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded down $15.01 on Wednesday, hitting $554.89. 693,104 shares of the stock were exchanged, compared to its average volume of 1,117,104. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.60 and a quick ratio of 4.73. The business's fifty day moving average is $537.05 and its 200 day moving average is $601.77. Regeneron Pharmaceuticals, Inc. has a 52 week low of $476.49 and a 52 week high of $1,211.20. The company has a market capitalization of $59.91 billion, a PE ratio of 13.98, a P/E/G ratio of 2.14 and a beta of 0.33.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its quarterly earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The firm had revenue of $3,675,600 billion for the quarter, compared to analyst estimates of $3.30 billion. During the same period in the prior year, the firm posted $11.56 earnings per share. The company's quarterly revenue was up 3.6% compared to the same quarter last year. Research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, September 3rd. Shareholders of record on Monday, August 18th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.6%. The ex-dividend date of this dividend is Monday, August 18th. Regeneron Pharmaceuticals's dividend payout ratio is 8.87%.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on the stock. UBS Group reissued a "neutral" rating on shares of Regeneron Pharmaceuticals in a research note on Friday, August 1st. Cantor Fitzgerald started coverage on shares of Regeneron Pharmaceuticals in a report on Tuesday, April 22nd. They set an "overweight" rating and a $695.00 price objective for the company. Wells Fargo & Company cut shares of Regeneron Pharmaceuticals from an "overweight" rating to an "equal weight" rating and set a $580.00 price objective for the company. in a report on Friday, August 1st. Canaccord Genuity Group restated a "buy" rating and set a $850.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, July 23rd. Finally, Wall Street Zen cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 1st. One analyst has rated the stock with a sell rating, seven have assigned a hold rating, sixteen have issued a buy rating and two have issued a strong buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $841.30.

Read Our Latest Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Profile

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Further Reading

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines